Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy

Amreddy, 2017, Polymeric nanoparticle-mediated gene delivery for lung cancer treatment, Top. Curr. Chem., 375, 35, 10.1007/s41061-017-0128-5

Amreddy, 2018, Recent advances in nanoparticle-based cancer drug and gene delivery, Adv. Cancer Res., 137, 115, 10.1016/bs.acr.2017.11.003

Antolin, 2020, The kinase polypharmacology landscape of clinical PARP inhibitors, Sci. Rep., 10, 2585, 10.1038/s41598-020-59074-4

Balasubramaniam, 2017, FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer, Clin. Cancer Res., 23, 7165, 10.1158/1078-0432.CCR-17-1337

Baldwin, , Nanoformulation of talazoparib increases maximum tolerated doses in combination with temozolomide for treatment of ewing sarcoma, Front. Oncol., 9, 1416, 10.3389/fonc.2019.01416

Baldwin, 2016, Abstract 4335: Nanoformulations of PARP inhibitors Olaparib and Talazoparib for targeted cancer therapy, Cancer Res., 76, 4335, 10.1158/1538-7445.AM2016-4335

Baldwin, , Nanoformulation of talazoparib delays tumor progression and ascites formation in a late stage cancer model, Front. Oncol., 9, 353, 10.3389/fonc.2019.00353

Baldwin, 2018, Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment, Int. J. Nanomed., 13, 8063, 10.2147/IJN.S186881

Baldwin, 2017, Generation of dose-response curves and improved IC50s for PARP inhibitor nanoformulations, Methods Mol. Biol., 1530, 337, 10.1007/978-1-4939-6646-2_20

Baretti, 2018, DNA mismatch repair in cancer, Pharmacol. Ther., 189, 45, 10.1016/j.pharmthera.2018.04.004

Bellini, 2014, Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in cancer cells, J. Control. Release, 196, 184, 10.1016/j.jconrel.2014.10.002

Blagosklonny, 2004, Analysis of FDA approved anticancer drugs reveals the future of cancer therapy, Cell Cycle, 3, 1035, 10.4161/cc.3.8.1023

Brown, 2017, Targeting DNA repair in cancer: beyond PARP inhibitors, Cancer Discov., 7, 20, 10.1158/2159-8290.CD-16-0860

Caster, 2015, Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity, Nanoscale, 7, 2805, 10.1039/C4NR07102F

Cheng, 2019, Recent development of CDK inhibitors: an overview of CDK/inhibitor co-crystal structures, Eur. J. Med. Chem., 164, 615, 10.1016/j.ejmech.2019.01.003

D'Andrea, 2018, Mechanisms of PARP inhibitor sensitivity and resistance, DNA Rep., 71, 172, 10.1016/j.dnarep.2018.08.021

Dinavahi, 2019, Aldehyde dehydrogenase inhibitors for cancer therapeutics, Trends Pharmacol. Sci., 40, 774, 10.1016/j.tips.2019.08.002

Du, 2018, Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation, ACS Nano, 12, 10785, 10.1021/acsnano.8b01573

Faraoni, 2018, Role of BRCA mutations in cancer treatment with Poly(ADP-ribose) Polymerase (PARP) inhibitors, Cancers, 10, 487, 10.3390/cancers10120487

Faria, 2018, The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling, Oncotarget, 9, 36273, 10.18632/oncotarget.26345

Gerber, 2008, Targeted therapies: a new generation of cancer treatments, Am. Fam. Phys., 77, 311

Geretto, 2017, Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators, Am. J. Cancer Res., 7, 1350

Ghasemiyeh, 2018, Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages, Res. Pharm. Sci., 13, 288, 10.4103/1735-5362.235156

Gibson, 2012, New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs, Nat. Rev. Mol. Cell Biol., 13, 411, 10.1038/nrm3376

Gonzales, 2018, Nanoemulsion-based delivery of fluorescent PARP inhibitors in mouse models of small cell lung cancer, Bioconjug. Chem., 29, 3776, 10.1021/acs.bioconjchem.8b00640

Guney Eskiler, 2018, Synthetically Lethal BMN 673 (Talazoparib) loaded solid lipid nanoparticles for BRCA1 mutant triple negative breast cancer, Pharm. Res., 35, 218, 10.1007/s11095-018-2502-6

Gwynne, 2017, Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts, Oncotarget, 8, 32101, 10.18632/oncotarget.16646

Hu, 2019, Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance, Oncogene, 38, 1951, 10.1038/s41388-018-0557-9

Ison, 2018, FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy, Clin. Cancer Res., 24, 4066, 10.1158/1078-0432.CCR-18-0042

Jachimowicz, 2019, DNA double-strand break repair pathway choice - from basic biology to clinical exploitation, Cell Cycle, 18, 1423, 10.1080/15384101.2019.1618542

Jaiswal, 2015, Nanoemulsion: an advanced mode of drug delivery system, 3 Biotech, 5, 123, 10.1007/s13205-014-0214-0

Jeelani, 2014, Theranostics: a treasured tailor for tomorrow, J. Pharm. Bioallied. Sci., 6, S6, 10.4103/0975-7406.137249

Jeong, 2013, United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies, Curr. Probl. Cancer, 37, 110, 10.1016/j.currproblcancer.2013.06.001

Kim, 2015, FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy, Clin. Cancer Res., 21, 4257, 10.1158/1078-0432.CCR-15-0887

pH-dependent structures of ferritin and apoferritin in solution: disassembly and reassembly16291640 KimM. RhoY. JinK. S. AhnB. JungS. KimH. 10.1021/bm200026v21446722Biomacromolecules122011

Kinch, 2014, An analysis of FDA-approved drugs for oncology, Drug Discov. Today, 19, 1831, 10.1016/j.drudis.2014.08.007

Kopecka, 2020, Phospholipids and cholesterol: inducers of cancer multidrug resistance and therapeutic targets, Drug Resist. Updat, 49, 100670, 10.1016/j.drup.2019.100670

Li, 2016, Constructing aptamer anchored nanovesicles for enhanced tumor penetration and cellular uptake of water soluble chemotherapeutics, Acta Biomater., 35, 269, 10.1016/j.actbio.2016.02.012

Liu, 2019, Food-grade nanoemulsions: preparation, stability and application in encapsulation of bioactive compounds, Molecules, 24, 4242, 10.3390/molecules24234242

Lord, 2017, PARP inhibitors: synthetic lethality in the clinic, Science, 355, 1152, 10.1126/science.aam7344

Mateo, 2019, A decade of clinical development of PARP inhibitors in perspective, Ann. Oncol., 30, 1437, 10.1093/annonc/mdz192

Mazzucchelli, 2017, H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer, Sci. Rep., 7, 7505, 10.1038/s41598-017-07617-7

McCann, 2018, Advances in the use of PARP inhibitor therapy for breast cancer, Drugs Context, 7, 212540, 10.7573/dic.212540

Mehra, 2018, Development and evaluation of talazoparib nanoemulsion for systemic therapy of BRCA1-mutant cancer, Anticancer Res., 38, 4493, 10.21873/anticanres.12753

Mensah, 2019, Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer, Bioeng. Transl. Med., 4, e10131, 10.1002/btm2.10131

Morales, 2014, Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases, Crit. Rev. Eukaryot. Gene Expr., 24, 15, 10.1615/CritRevEukaryotGeneExpr.2013006875

Muhamad, 2018, Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review, Int. J. Nanomed., 13, 3921, 10.2147/IJN.S165210

Naseri, 2015, Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application, Adv. Pharm. Bull., 5, 305, 10.15171/apb.2015.043

Novohradsky, 2018, Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells, Oncotarget, 9, 28456, 10.18632/oncotarget.25466

Oh, 2013, The multilayer nanoparticles formed by layer by layer approach for cancer-targeting therapy, J. Control. Release, 165, 9, 10.1016/j.jconrel.2012.10.013

Ossovskaya, 2010, Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types, Genes Cancer, 1, 812, 10.1177/1947601910383418

Pantelidou, 2019, PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via Intratumoral STING pathway activation in BRCA-Deficient models of triple-negative breast cancer, Cancer Discov., 9, 722, 10.1158/2159-8290.CD-18-1218

Patel, 2020, The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review, Cell Biosci., 10, 35, 10.1186/s13578-020-00390-7

Pathade, 2019, Preparation and comparison of oral bioavailability for different nano-formulations of olaparib, AAPS PharmSciTech, 20, 276, 10.1208/s12249-019-1468-y

Pillai, 2014, Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development, SOJ Pharm. Pharmaceut. Sci., 1, 10.15226/2374-6866/1/2/00109

Piñón-Segundo, 2012, Pharmaceutical polymeric nanoparticles prepared by the double emulsion- solvent evaporation technique, Recent Pat. Drug Deliv. Formul., 6, 224, 10.2174/187221112802652606

Prendergast, 2018, Indoleamine 2,3-Dioxygenase and its therapeutic inhibition in cancer, Int. Rev. Cell Mol. Biol., 336, 175, 10.1016/bs.ircmb.2017.07.004

Ray Chaudhuri, 2017, The multifaceted roles of PARP1 in DNA repair and chromatin remodeling, Nat. Rev. Mol. Cell Biol., 18, 610, 10.1038/nrm.2017.53

Riley, 2019, Delivery technologies for cancer immunotherapy, Nat. Rev. Drug Discov., 18, 175, 10.1038/s41573-018-0006-z

Salaroglio, 2017, PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy, Mol. Cancer, 16, 91, 10.1186/s12943-017-0657-0

Savage, 2015, BRCA1, a 'complex' protein involved in the maintenance of genomic stability, FEBS J., 282, 630, 10.1111/febs.13150

Schreiber, 2006, Poly(ADP-ribose): novel functions for an old molecule, Nat. Rev. Mol. Cell Biol., 7, 517, 10.1038/nrm1963

Siegel, 2020, Cancer statistics, 2020, CA Cancer J. Clin., 70, 7, 10.3322/caac.21590

Smith, 2015, Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program, Clin. Cancer Res., 21, 819, 10.1158/1078-0432.CCR-14-2572

Song, 2018, Recent development of small molecule glutaminase inhibitors, Curr. Top. Med. Chem., 18, 432, 10.2174/1568026618666180525100830

Spring, 2019, CDK 4/6 inhibitors in breast cancer: current controversies and future directions, Curr. Oncol. Rep., 21, 25, 10.1007/s11912-019-0769-3

Sun, 2012, Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystals, Int. J. Nanomed., 7, 5733, 10.2147/IJN.S34365

Sun, 2017, A systematic analysis of FDA-approved anticancer drugs, BMC Syst. Biol., 11, 87, 10.1186/s12918-017-0464-7

Tangutoori, 2015, PARP inhibitors: a new era of targeted therapy, Maturitas, 81, 5, 10.1016/j.maturitas.2015.01.015

Tayeb, 2018, Nanoemulsions in drug delivery: formulation to medical application, Nanomedicine, 13, 2507, 10.2217/nnm-2018-0088

Valencia, 2010, Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing, ACS Nano, 4, 1671, 10.1021/nn901433u

van de Ven, 2017, Nanoformulation of Olaparib Amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation, Mol. Cancer Ther., 16, 1279, 10.1158/1535-7163.MCT-16-0740

Ventola, 2012, The nanomedicine revolution: part 1: emerging concepts, P T, 37, 512

Ventola, 2017, Progress in nanomedicine: approved and investigational nanodrugs, P T, 42, 742

Wang, 2017, Functional ferritin nanoparticles for biomedical applications, Front. Chem. Sci. Eng., 11, 633, 10.1007/s11705-017-1620-8

White, 2019, Nanoparticle activation methods in cancer treatment, Biomolecules, 9, 202, 10.3390/biom9050202

Yoon, 2013, Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery, J. Pharm. Invest., 43, 353, 10.1007/s40005-013-0087-y

Zhang, 2019, A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice, Theranostics, 9, 6224, 10.7150/thno.36281

Zhang, 2020, Role of DNA repair defects in predicting immunotherapy response, Biomark Res., 8, 23, 10.1186/s40364-020-00202-7

Zhang, 2008, Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform, ACS Nano, 2, 1696, 10.1021/nn800275r

Zielińska, 2020, Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology, Molecules, 25, 3731, 10.3390/molecules25163731